Back to Search
Start Over
Dupilumab Provides Rapid and Sustained Clinically Meaningful Responses in Adults with Moderate-to-severe Atopic Dermatitis
- Source :
- Acta Dermato-Venereologica, Vol 101, Iss 11 (2021)
- Publication Year :
- 2021
- Publisher :
- Medical Journals Sweden AB, 2021.
-
Abstract
- Optimal management of atopic dermatitis requires a comprehensive assessment of response to treatment in order to inform therapeutic decisions. In a real-world setting, successful response to atopic dermatitis treatment is measured by sustained improvements in signs, symptoms, and quality of life. Post-hoc analyses of a 1-year, randomized, double-blinded, placebo- controlled trial (NCT02260986) of dupilumab with concomitant topical corticosteroids in 421 adults with moderate-to-severe atopic dermatitis (of whom 315/106 received placebo/dupilumab (of whom 315 received placebo and 106 received dupilumab) was performed to assess the proportion of responders to dupilumab through a multidimensional composite endpoint. At 6-months, 80.2% of dupilumab-treated vs 40.0% placebo patients (p
- Subjects :
- Adult
treat-to-target
medicine.medical_specialty
Eczema
responder
Dermatology
Antibodies, Monoclonal, Humanized
Placebo
Severity of Illness Index
Eczema Area and Severity Index
Dermatitis, Atopic
law.invention
Double-Blind Method
Quality of life
Randomized controlled trial
law
Internal medicine
Severity of illness
medicine
Humans
Randomized Controlled Trials as Topic
atopic dermatitis
business.industry
General Medicine
Dermatology Life Quality Index
Atopic dermatitis
pruritus
medicine.disease
Dupilumab
body regions
Treatment Outcome
RL1-803
Quality of Life
business
Subjects
Details
- ISSN :
- 16512057 and 00015555
- Volume :
- 101
- Database :
- OpenAIRE
- Journal :
- Acta Dermato-Venereologica
- Accession number :
- edsair.doi.dedup.....1fd2ed294b0bd2b7a93fc3f86563367d